Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Charles River Laboratories Intl (NY: CRL )

180.96 +2.38 (+1.33%)
Official Closing Price Updated: 7:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 830,357
Open 180.40
Bid (Size) 176.82 (1)
Ask (Size) 185.62 (1)
Prev. Close 178.58
Today's Range 179.46 - 184.04
52wk Range 166.87 - 275.00
Shares Outstanding 50,396,622
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
P/E Ratio Insights for Charles River
Via Benzinga
This Ferguson Enterprises Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Via Benzinga

Performance

YTD
-22.75%
-22.75%
1 Month
-4.55%
-4.55%
3 Month
-20.07%
-20.07%
6 Month
-23.08%
-23.08%
1 Year
-0.52%
-0.52%

More News

Read More
Charles River Launches New Retrogenix® Non-Human Protein Library
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories Schedules Third-Quarter 2024 Earnings Release and Conference Call
From Charles River Laboratories International, Inc.
Via Business Wire
Evaluating Charles River: Insights From 12 Financial Analysts
Via Benzinga
The Analyst Verdict: Charles River In The Eyes Of 10 Experts
Via Benzinga
This Alibaba Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Via Benzinga
This Netflix Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday
Via Benzinga
Charles River Provides Translational Expertise at Neuroscience 2024
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River and Lundbeck Enter Agreement Utilizing AI-Powered Logica® to Advance the Discovery of Novel Drugs for Neurological Disease
From Charles River Laboratories International, Inc.
Via Business Wire
Critical Insights From Charles River Analyst Ratings: What You Need To Know
Via Benzinga
Charles River Laboratories and CEBINA Announce Strategic Collaboration to Accelerate Cutting Edge Neuroscience Research
From Charles River Laboratories International, Inc.
Via Business Wire
Intel, Moderna And Dollar General Were Among Top 10 Large Cap Losers In August: Are The Others In Your Portfolio?
Via Benzinga
Charles River and Insightec Announce Strategic Collaboration to Advance Therapeutic Development Utilizing Focused Ultrasound in Neuroscience
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories to Present at Baird and Morgan Stanley Conferences
From Charles River Laboratories International, Inc.
Via Business Wire
Magnificent 7 Miss Out, 2 Cybersecurity Stocks Stand Firm, Retailers Lag In Volatile August: Here Are The Top S&P 500 Gainers And Losers
Via Benzinga
Topics Stocks
Exposures US Equities
CHARLES RIVER ALERT: Bragar Eagel & Squire, P.C. is Investigating Charles River Laboratories International, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Warner Bros, Airbnb And Monster Beverage Are Among Top 10 Large Cap Losers Last Week (Aug 4-Aug 10): Are The Others In Your Portfolio?
Via Benzinga
EXCLUSIVE: Oragenics' Concussion Drug Clears FDA-Required Cardiotoxicity Testing, Planning For Phase Trials Underway
Via Benzinga
Boot Barn To Rally Around 27%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
Wall Street Ends Wednesday In The Red As Risk Sentiment Remains Fragile: S&P 500 Movers At The Close
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Charles River Laboratories Stock Sinks As It Warns Of Continued Biotech Demand Slump, Lowers Forecast
Via Benzinga
Charles River Labs Plummets 17% On 'Bleaker' Expectations For 2024
Via Investor's Business Daily
Charles River Laboratories Announces Second-Quarter 2024 Results
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Collaborates with Patient Advocacy Group, FOXG1 Research Foundation to Advance Rare Disease Gene Therapy Development
From Charles River Laboratories International, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.